NCT06097390

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

A Study Investigating the Pharmacokinetic Properties When Dosing Different Formulations of Semaglutide to Healthy Male Participants - Oral Formulation III

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 121 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Male
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

In this study, a known medicine called 'semaglutide' will be tested in two different tablet versions. The two tablets differ in the way these have been manufactured. The aim of the study is to investigate the amount of active ingredient in the blood after dosing the different tablet versions. Participants will receive one tablet version for 10 days (first treatment period) and the other version for 10 days (second treatment period). The treatment arm participants will be assigned to is decided by chance. The study will last for about 23 weeks for each participant. The study will enroll healthy male participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	Semaglutide	Oral administration

Timeline

• Start date: 2023-09-28
• Primary completion: 2024-02-22
• Completion: 2024-03-27
• First posted: 2023-10-24
• Last updated: 2025-07-17

Locations

1 site across 1 country: Canada